

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Inventors	: M. TAKEDA et al.	<u>Certificate of Correction Branch</u>
Patent No.	: 7,022,893	Issued: April 4, 2006
Serial No.	: 09/581,528	I.A. Filed: January 7, 1999 (U.S. National Stage entry of PCT/JP99/00015)
For	: KNICKIN GENE-MUTATED MOUSE COMPRISING A MUTANT PRESENILIN-1 GENE	

**REQUEST FOR CERTIFICATE OF CORRECTION AND
FOR REPRINTING OF LETTERS PATENT**

Commissioner for Patents
U.S. Patent and Trademark Office
Customer Service Window
Randolph Building
401 Dulany Street
Alexandria, VA 22314

Sir:

Please find attached a proposed Certificate of Correction.

Please correct the following errors appearing in the printed patent. These errors are apparently the fault of the U.S. Patent and Trademark Office, as per the attached Certificate of Correction. In view of the extensive errors in the patent, it is requested that the patent be reprinted.

On the cover of the printed patent, item (56), References Cited, “6,395,960” should be --- 6,395,690---. This appeared correctly on the Form PTO-892 attached to the Office Action mailed November 8, 2002.

At column 35, line 26 (claim 1, line 1) of the printed patent, “having” should be ---whose genome comprises---. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 35, line 27 (claim 1, line 2) of the printed patent, after “wherein” insert ---expression of---. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 35, line 28 (claim 1, line 3) of the printed patent, “overexpression” should be ---accumulation---. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 35, line 31 (claim 2, line 2) of the printed patent, “animal” should be ---mouse---. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 35, line 32 (claim 2, line 3) of the printed patent, after “DNA” delete “having a”. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 35, line 36 (claim 3, line 1) of the printed patent, after “The” delete “non human”. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 35, line 37 (claim 3, line 2) of the printed patent, “has” should be ---genome comprises---. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 35, line 38 (claim 3, line 3) of the printed patent, after “encoding” delete “around”. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 35, lines 39-40 (claim 3, lines 4-5) of the printed patent, “in an amino acid sequence of the presenilin-1 protein” should be ---of a mouse presenilin-1 protein as set forth in

SEQ ID NO: 3---. This appeared correctly on the Examiner's Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 35, line 42 (claim 3, line 6) of the printed patent, "5'-TGTGGTCGGGATGATYGCC AVC CACTGGAAAGGCC-3' (SEQ ID NO: 18)" should be ---5'-TGTGGTCGGGATGATYGCC AVC CACTGGAAAGGCC-3' (SEQ ID NO: 18)---. This appeared correctly on the Examiner's Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 35, line 45 (claim 3, line 9) of the printed patent, "the underlined bases" should be ---wherein AVC---. This appeared correctly on the Examiner's Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 35, line 47 (claim 4, line 1) of the printed patent, after "The" delete "non human". This appeared correctly on the Examiner's Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 35, line 48 (claim 4, line 2) of the printed patent, "has" should be ---genome comprises---. This appeared correctly on the Examiner's Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 35, line 49 (claim 4, line 3) of the printed patent, after "encoding" delete "around". This appeared correctly on the Examiner's Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 35, lines 50-51 (claim 4, lines 4-5) of the printed patent, "in an amino acid sequence of the presenilin-1 protein" should be ---of a mouse presenilin-1 protein as set forth in SEQ ID NO: 3---. This appeared correctly on the Examiner's Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 35, line 52 (claim 4, line 6) of the printed patent, “5'-TGTTGTCGGGATGATMGCC ACC CACTGGAAAGGCC-3' (SEQ ID NO: 19)” should be ---5'-TGTTGTCGGGATGATYGCC ACC CACTGGAAAGGCC-3' (SEQ ID NO: 19)---. This appeared correctly on the Examiner's Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 35, line 54 (claim 4, line 8) of the printed patent, “the underlined bases” should be ---wherein ACC---. This appeared correctly on the Examiner's Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 35, line 57 (claim 5, line 2) of the printed patent, “has” should be ---genome comprises---. This appeared correctly on the Examiner's Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 35, line 58 (claim 5, line 3) of the printed patent, after “encoding” delete “around”. This appeared correctly on the Examiner's Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 35, lines 58-59 (claim 5, lines 3-4) of the printed patent, “in an amino acid sequence of the presenilin-1 protein” should be ---of a mouse presenilin-1 protein as set forth in SEQ ID NO: 3---. This appeared correctly on the Examiner's Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 35, line 62 (claim 5, line 6) of the printed patent, “5'-TGTTGTCGGGATGATYGCC NNN CACTGGAAAGGCC-3' (SEQ ID NO: 20)” should be ---5'-TGTTGTCGGGATGATYGCC NNN CACTGGAAAGGCC-3' (SEQ ID NO: 20)---. This appeared correctly on the Examiner's Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 35, line 67 (claim 5, line 11) of the printed patent, “the underlined bases” should be ---wherein NNN---. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 36, line 25 (claim 6, line 1) of the printed patent, after “The” delete “non human”. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 36, line 26 (claim 6, line 2) of the printed patent, after “transferred” insert --- into a mouse ES cell genome---. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 36, line 28 (claim 7, line 1) of the printed patent, “having” should be ---whose genome comprises---. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 36, line 29 (claim 7, line 2) of the printed patent, after “DNA” delete “having a”. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 36, line 33 (claim 7, line 6) of the printed patent, after “wherein” insert --- expression of---. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 36, line 34 (claim 7, line 7) of the printed patent, “overexpression” should be --accumulation---. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 36, line 37 (claim 8, line 1) of the printed patent, “having” should be ---whose genome comprises---. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 36, line 38 (claim 8, line 2) of the printed patent, after “DNA” delete “having”. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 36, line 42 (claim 8, line 6) of the printed patent, after “wherein” add ---expression of---. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 36, lines 42-43 (claim 8, lines 6-7) of the printed patent, “overexpression” should be ---accumulation---. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 36, line 45 (claim 9, line 1) of the printed patent, “having” should be ---whose genome comprises---. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 36, line 46 (claim 9, line 2) of the printed patent, “the” should be ---an---. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 36, line 47 (claim 9, line 3) of the printed patent, after “wherein” add ---expression of---. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 36, lines 47-48 (claim 9, lines 3-4) of the printed patent, “overexpression” should be ---accumulation---. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 36, line 53 (claim 10, line 4) of the printed patent, after “mouse” add ---whose genome comprises a mutant presenilin-1 gene---. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 36, line 59 (claim 10, line 10) of the printed patent, after “mouse” add ---whose genome comprises a mutant presenilin-1 gene---. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 37, line 4 (claim 12, line 2) of the printed patent, after “cell” add ---comprising a mutant presenilin-1 gene---. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 37, line 4 (claim 12, line 2) of the printed patent, after “mouse” add ---whose genome comprises a mutant presenilin-1 gene---. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 37, line 5 (claim 12, line 3) of the printed patent, after “culture” add ---,wherein expression of the mutant presenilin-1 gene results in accumulation of Amyloid β 42 in said culture---. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 37, line 8 (claim 13, line 3) of the printed patent, delete “the step of”. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 37, line 8, (claim 13, line 3) of the printed patent, after “culture” add --- comprising a mutant presenilin-1 gene---. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 37, line 9 (claim 13, line 4) of the printed patent, after “cell” add --- comprising a mutant presenilin-1 gene---. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 37, line 10 (claim 13, line 5) of the printed patent, after “subcultured cell” add ---; and determining effect of said test compound on Amyloid β 42 formation in the cell culture or the subcultured cell---. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 37, line 11 (claim 14, line 1) of the printed patent, after “An” add ---isolated mouse---. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 37, line 11 (claim 14, line 1) of the printed patent, “introduced with a plasmid comprising” should be ---whose genome comprises---. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 37, line 12 (claim 14, line 2) of the printed patent, after “DNA” add --- sequence---. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 37, line 16 (claim 15, line 1) of the printed patent, after “an” add ---isolated mouse---. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 37, line 16 (claim 15, line 1) of the printed patent, after “embryo” add ---of claim 14---. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 37, lines 16-17 (claim 15, lines 1-2) of the printed patent, “homologous recombination using the plasmid according to claim 1.” should be ---insertion of a mouse ES cell comprising a DNA sequence represented by the nucleotide sequence: 5’-

TGTGGTCGGGATGATYGCCACCCACTGGAAAGGCCC-3’ (SEQ ID NO: 19)

wherein Y represents T or C---. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 38, line 1 (claim 16, line 1) of the printed patent, after “gene-mutated” add ---presenilin-1---. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

At column 38, line 2 (claim 16, line 2) of the printed patent, delete lines 2-9 in its entirety and add ---comprising introducing a DNA sequence encoding a presenilin-1 mutation into mouse ES cells, permitting the DNA sequence to undergo homologous recombination with the genome of said ES cell, thereby inserting the presenilin-1 mutation into the endogenous presenilin-1 gene, transferring said ES cell comprising the mutant presenilin-1 into a mouse embryo, transferring the embryo to a female mouse and developing the mouse to term---. This appeared correctly on the Examiner’s Amendment attached to the Notice of Allowance mailed October 11, 2005.

Therefore, it is respectfully requested that a Certificate of Correction issue in the above-identified patent as follows:

On the cover of the printed patent, item (56), References Cited, “6,395,960” should be ---6,395,690---.

At column 35, line 26 (claim 1, line 1) of the printed patent, “having” should be ---whose genome comprises---.

At column 35, line 27 (claim 1, line 2) of the printed patent, after “wherein” insert ---expression of---.

At column 35, line 28 (claim 1, line 3) of the printed patent, “overexpression” should be ---accumulation---.

At column 35, line 31 (claim 2, line 2) of the printed patent, “animal” should be ---mouse---.

At column 35, line 32 (claim 2, line 3) of the printed patent, after “DNA” delete “having a”.

At column 35, line 36 (claim 3, line 1) of the printed patent, after “The” delete “non human”.

At column 35, line 37 (claim 3, line 2) of the printed patent, “has” should be ---genome comprises---.

At column 35, line 38 (claim 3, line 3) of the printed patent, after “encoding” delete “around”.

At column 35, lines 39-40 (claim 3, lines 4-5) of the printed patent, “in an amino acid sequence of the presenilin-1 protein” should be ---of a mouse presenilin-1 protein as set forth in SEQ ID NO: 3---.

At column 35, line 42 (claim 3, line 6) of the printed patent,

“5′-TGTGGTCGGGATGATYGCC AVC CACTGGAAAGGCC-3′ (SEQ ID NO: 18)” should be ---5′-TGTGGTCGGGATGATYGCC AVC CACTGGAAAGGCC-3′ (SEQ ID NO: 18)---.

At column 35, line 45 (claim 3, line 9) of the printed patent, “the underlined bases” should be ---wherein AVC---.

At column 35, line 47 (claim 4, line 1) of the printed patent, after “The” delete “non human”.

At column 35, line 48 (claim 4, line 2) of the printed patent, “has” should be ---genome comprises---.

At column 35, line 49 (claim 4, line 3) of the printed patent, after “encoding” delete “around”.

At column 35, lines 50-51 (claim 4, lines 4-5) of the printed patent, “in an amino acid sequence of the presenilin-1 protein” should be ---of a mouse presenilin-1 protein as set forth in SEQ ID NO: 3---.

At column 35, line 52 (claim 4, line 6) of the printed patent, “5′-TGTGGTCGGGATGATMGCC ACC CACTGGAAAGGCC-3′ (SEQ ID NO: 19)” should be ---5′-TGTGGTCGGGATGATYGCC ACC CACTGGAAAGGCC-3′ (SEQ ID NO: 19)---. At column 35, line 54 (claim 4, line 8) of the printed patent, “the underlined bases” should be ---wherein ACC---.

At column 35, line 57 (claim 5, line 2) of the printed patent, “has” should be ---genome comprises---.

At column 35, line 58 (claim 5, line 3) of the printed patent, after “encoding” delete “around”.

At column 35, lines 58-59 (claim 5, lines 3-4) of the printed patent, “in an amino acid sequence of the presenilin-1 protein” should be ---of a mouse presenilin-1 protein as set forth in SEQ ID NO: 3---.

At column 35, line 62 (claim 5, line 6) of the printed patent, “5’-TGTGGTCGGGATGATYGCC NNN CACTGGAAAGGCCC-3’ (SEQ ID NO: 20)” should be ---5’-TGTGGTCGGGATGATYGCC NNN CACTGGAAAGGCCC-3’ (SEQ ID NO: 20)---.

At column 35, line 67 (claim 5, line 11) of the printed patent, “the underlined bases” should be ---wherein NNN---.

At column 36, line 25 (claim 6, line 1) of the printed patent, after “The” delete “non human”.

At column 36, line 26 (claim 6, line 2) of the printed patent, after “transferred” insert --- into a mouse ES cell genome---.

At column 36, line 28 (claim 7, line 1) of the printed patent, “having” should be ---whose genome comprises---.

At column 36, line 29 (claim 7, line 2) of the printed patent, after “DNA” delete “having a”.

At column 36, line 33 (claim 7, line 6) of the printed patent, after “wherein” insert --- expression of---.

At column 36, line 34 (claim 7, line 7) of the printed patent, “overexpression” should be - --accumulation---.

At column 36, line 37 (claim 8, line 1) of the printed patent, “having” should be ---whose genome comprises---.

At column 36, line 38 (claim 8, line 2) of the printed patent, after “DNA” delete “having”.

At column 36, line 42 (claim 8, line 6) of the printed patent, after “wherein” add ---expression of---.

At column 36, lines 42-43 (claim 8, lines 6-7) of the printed patent, “overexpression” should be ---accumulation---.

At column 36, line 45 (claim 9, line 1) of the printed patent, “having” should be ---whose genome comprises---.

At column 36, line 46 (claim 9, line 2) of the printed patent, “the” should be ---an---.

At column 36, line 47 (claim 9, line 3) of the printed patent, after “wherein” add ---expression of---.

At column 36, lines 47-48 (claim 9, lines 3-4) of the printed patent, “overexpression” should be ---accumulation---.

At column 36, line 53 (claim 10, line 4) of the printed patent, after “mouse” add ---whose genome comprises a mutant presenilin-1 gene---.

At column 36, line 59 (claim 10, line 10) of the printed patent, after “mouse” add ---whose genome comprises a mutant presenilin-1 gene---.

At column 37, line 4 (claim 12, line 2) of the printed patent, after “cell” add ---comprising a mutant presenilin-1 gene---.

At column 37, line 4 (claim 12, line 2) of the printed patent, after “mouse” add ---whose genome comprises a mutant presenilin-1 gene---.

At column 37, line 5 (claim 12, line 3) of the printed patent, after “culture” add ---,wherein expression of the mutant presenilin-1 gene results in accumulation of Amyloid β 42 in said culture---.

At column 37, line 8 (claim 13, line 3) of the printed patent, delete “the step of”.

At column 37, line 8, (claim 13, line 3) of the printed patent, after “culture” add --- comprising a mutant presenilin-1 gene---.

At column 37, line 9 (claim 13, line 4) of the printed patent, after “cell” add --- comprising a mutant presenilin-1 gene---.

At column 37, line 10 (claim 13, line 5) of the printed patent, after “subcultured cell” add ---; and determining effect of said test compound on Amyloid β 42 formation in the cell culture or the subcultured cell---.

At column 37, line 11 (claim 14, line 1) of the printed patent, after “An” add ---isolated mouse---.

At column 37, line 11 (claim 14, line 1) of the printed patent, “introduced with a plasmid comprising” should be ---whose genome comprises---.

At column 37, line 12 (claim 14, line 2) of the printed patent, after “DNA” add --- sequence---.

At column 37, line 16 (claim 15, line 1) of the printed patent, after “an” add ---isolated mouse---.

At column 37, line 16 (claim 15, line 1) of the printed patent, after “embryo” add ---of claim 14---.

At column 37, lines 16-17 (claim 15, lines 1-2) of the printed patent, “homologous recombination using the plasmid according to claim 1.” should be ---insertion of a mouse ES cell

comprising a DNA sequence represented by the nucleotide sequence: 5'-
TGTGGTCGGGATGATYGCCACCCACTGGAAAGGCCC-3' (SEQ ID NO: 19)
wherein Y represents T or C.---


At column 38, line 1 (claim 16, line 1) of the printed patent, after "gene-mutated" add ---
presenilin-1---

At column 38, line 2 (claim 16, line 2) of the printed patent, delete lines 2-9 in its entirety
and add ---comprising introducing a DNA sequence encoding a presenilin-1 mutation into mouse
ES cells, permitting the DNA sequence to undergo homologous recombination with the genome
of said ES cell, thereby inserting the presenilin-1 mutation into the endogenous presenilin-1
gene, transferring said ES cell comprising the mutant presenilin-1 into a mouse embryo,
transferring the embryo to a female mouse and developing the mouse to term.---

Since the errors are the fault of the U.S. Patent and Trademark Office, no fee is believed
to be necessary for the requested Certificate of Correction and Reprinting of the Patent.
However, if any fees are necessary for Reprinting of the Patent, authorization is hereby provided
to charge any required fee to Deposit Account No. 19-0089.

Should there be any questions, the Examiner is invited to contact the undersigned at the
below-listed number.

Respectfully submitted,
M. TAKEDA et al.


Bruce H. Bernstein
Reg. No. 29,027

August 17, 2007
GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

Arnold Turk
Reg. No. 33094

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 1 of 6

PATENT NO. : 7,022,893 B1
APPLICATION NO.: 09/581,528
ISSUE DATE : April 4, 2006
INVENTOR(S) : M. TAKEDA et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

On the cover of the printed patent, item (56), References Cited, "6,395,960" should be ---6,395,690---

At column 35, line 26 (claim 1, line 1) of the printed patent, "having" should be ---whose genome comprises---

At column 35, line 27 (claim 1, line 2) of the printed patent, after "wherein" insert ---expression of---

At column 35, line 28 (claim 1, line 3) of the printed patent, "overexpression" should be ---accumulation---

At column 35, line 31 (claim 2, line 2) of the printed patent, "animal" should be ---mouse---

At column 35, line 32 (claim 2, line 3) of the printed patent, after "DNA" delete "having a".

At column 35, line 36 (claim 3, line 1) of the printed patent, after "The" delete "non human".

At column 35, line 37 (claim 3, line 2) of the printed patent, "has" should be ---genome comprises---

At column 35, line 38 (claim 3, line 3) of the printed patent, after "encoding" delete "around".

At column 35, lines 39-40 (claim 3, lines 4-5) of the printed patent, "in an amino acid sequence of the presenilin-1 protein" should be ---of a mouse presenilin-1 protein as set forth in SEQ ID NO: 3---

At column 35, line 42 (claim 3, line 6) of the printed patent,
"5'-TGTGGTCTGGGATGATYGCC AVC CACTGGAAAGGCC-3' (SEQ ID NO: 18)" should be ---5'-TGTGGTCG
GGATGATYGCC AVC CACTGGAAAGGCC-3' (SEQ ID NO: 18)---

MAILING ADDRESS OF SENDER (Please do not use customer number below):

GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION

Page 3 of 6

PATENT NO. : 7,022,893 B1

APPLICATION NO.: 09/581,528

ISSUE DATE : April 4, 2006

INVENTOR(S) : M. TAKEDA et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

At column 35, line 62 (claim 5, line 6) of the printed patent,
"5'-TGTGGTCGGGATGATYGCC NNN CACTGGAAGGCC-3' (SEQ ID NO: 20)" should be ---5'-TGTGGTCG
GGATGATYGCC NNN CACTGGAAGGCC-3' (SEQ ID NO: 20)---.

At column 35, line 67 (claim 5, line 11) of the printed patent, "the underlined bases" should be ---wherein NNN---.

At column 36, line 25 (claim 6, line 1) of the printed patent, after "The" delete "non human".

At column 36, line 26 (claim 6, line 2) of the printed patent, after "transferred" insert ---into a mouse ES cell
genome---.

At column 36, line 28 (claim 7, line 1) of the printed patent, "having" should be ---whose genome comprises---.

At column 36, line 29 (claim 7, line 2) of the printed patent, after "DNA" delete "having a".

At column 36, line 33 (claim 7, line 6) of the printed patent, after "wherein" insert ---expression of---.

At column 36, line 34 (claim 7, line 7) of the printed patent, "overexpression" should be ---accumulation---.

At column 36, line 37 (claim 8, line 1) of the printed patent, "having" should be ---whose genome comprises---.

At column 36, line 38 (claim 8, line 2) of the printed patent, after "DNA" delete "having".

At column 36, line 42 (claim 8, line 6) of the printed patent, after "wherein" add ---expression of---.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 4 of 6

PATENT NO. : 7,022,893 B1
APPLICATION NO.: 09/581,528
ISSUE DATE : April 4, 2006
INVENTOR(S) : M. TAKEDA et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

At column 36, lines 42-43 (claim 8, lines 6-7) of the printed patent, "overexpression" should be ---accumulation---

At column 36, line 45 (claim 9, line 1) of the printed patent, "having" should be ---whose genome comprises---

At column 36, line 46 (claim 9, line 2) of the printed patent, "the" should be ---an---

At column 36, line 47 (claim 9, line 3) of the printed patent, after "wherein" add ---expression of---

At column 36, lines 47-48 (claim 9, lines 3-4) of the printed patent, "overexpression" should be ---accumulation---

At column 36, line 53 (claim 10, line 4) of the printed patent, after "mouse" add ---whose genome comprises a mutant presenilin-1 gene---

At column 36, line 59 (claim 10, line 10) of the printed patent, after "mouse" add ---whose genome comprises a mutant presenilin-1 gene---

At column 37, line 4 (claim 12, line 2) of the printed patent, after "cell" add ---comprising a mutant presenilin-1 gene---

At column 37, line 4 (claim 12, line 2) of the printed patent, after "mouse" add ---whose genome comprises a mutant presenilin-1 gene---

At column 37, line 5 (claim 12, line 3) of the printed patent, after "culture" add ---,wherein expression of the mutant presenilin-1 gene results in accumulation of Amyloid β 42 in said culture---

At column 37, line 8 (claim 13, line 3) of the printed patent, delete "the step of".

MAILING ADDRESS OF SENDER (Please do not use customer number below):

GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

UNITED STATES PATENT AND TRADEMARK OFFICE CERTIFICATE OF CORRECTION

Page 5 of 6

PATENT NO. : 7,022,893 B1

APPLICATION NO.: 09/581,528

ISSUE DATE : April 4, 2006

INVENTOR(S) : M. TAKEDA et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

At column 37, line 8, (claim 13, line 3) of the printed patent, after "culture" add ---comprising a mutant presenilin-1 gene---.

At column 37, line 9 (claim 13, line 4) of the printed patent, after "cell" add ---comprising a mutant presenilin-1 gene---.

At column 37, line 10 (claim 13, line 5) of the printed patent, after "subcultured cell" add ---; and determining effect of said test compound on Amyloid β 42 formation in the cell culture or the subcultured cell---.

At column 37, line 11 (claim 14, line 1) of the printed patent, after "An" add ---isolated mouse---.

At column 37, line 11 (claim 14, line 1) of the printed patent, "introduced with a plasmid comprising" should be ---whose genome comprises---.

At column 37, line 12 (claim 14, line 2) of the printed patent, after "DNA" add ---sequence---.

At column 37, line 16 (claim 15, line 1) of the printed patent, after "an" add ---isolated mouse---.

At column 37, line 16 (claim 15, line 1) of the printed patent, after "embryo" add ---of claim 14---.

At column 37, lines 16-17 (claim 15, lines 1-2) of the printed patent, "homologous recombination using the plasmid according to claim 1." should be ---insertion of a mouse ES cell comprising a DNA sequence represented by the nucleotide sequence: 5'-TGTGGTCGGGATGATYGCCACCACTGGAAGGCC-3' (SEQ ID NO: 19) wherein Y represents T or C---.

MAILING ADDRESS OF SENDER (Please do not use customer number below):

GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**UNITED STATES PATENT AND TRADEMARK OFFICE
CERTIFICATE OF CORRECTION**

Page 6 of 6

PATENT NO. : 7,022,893 B1
APPLICATION NO.: 09/581,528
ISSUE DATE : April 4, 2006
INVENTOR(S) : M. TAKEDA et al.

It is certified that an error appears or errors appear in the above-identified patent and that said Letters Patent is hereby corrected as shown below:

At column 38, line 1 (claim 16, line 1) of the printed patent, after "gene-mutated" add ---presenilin-1---

At column 38, line 2 (claim 16, line 2) of the printed patent, delete lines 2-9 in its entirety and add ---comprising introducing a DNA sequence encoding a presenilin-1 mutation into mouse ES cells, permitting the DNA sequence to undergo homologous recombination with the genome of said ES cell, thereby inserting the presenilin-1 mutation into the endogenous presenilin-1 gene, transferring said ES cell comprising the mutant presenilin-1 into a mouse embryo, transferring the embryo to a female mouse and developing the mouse to term.---

MAILING ADDRESS OF SENDER (Please do not use customer number below):

GREENBLUM & BERNSTEIN, P.L.C.
1950 Roland Clarke Place
Reston, VA 20191

This collection of information is required by 37 CFR 1.322, 1.323, and 1.324. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1.0 hour to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: **Attention Certificate of Corrections Branch, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.